Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids.
The effects of antiinflammatory steroids on arachidonic acid metabolite release from human lung fragments were analyzed. Incubation of lung fragments for 24 hr with 10(-6) M dexamethasone inhibited the net release of the prostacyclin metabolite 6-keto-PGF1 alpha, PGE2, and PGF2 alpha from lung fragments stimulated with anti-IgE but failed to inhibit the anti-IgE-induced release of PGD2, TXB2, and iLTC4. The IC50 of dexamethasone for inhibition of both spontaneous and anti-IgE-induced 6-keto-PGF1 alpha release was approximately 2 X 10(-8) M, and a 6-hr preincubation with the drug was required for 50% inhibition of prostaglandin release. Other agents were tested for activity in stimulating arachidonic acid metabolite release from human lung fragments. FMLP (fmet-leu-phe) stimulated the release of all metabolites tested (6-keto-PGF1 alpha, PGD2, PGE2, PGF2 alpha, TXB2, iLTC4); platelet-activating factor (PAF), but not lysoPAF, stimulated the release of PGD2, TXB2, and iLTC4. In contrast to the case with anti-IgE, where dexamethasone failed to inhibit net PGD2 and TXB2 release, the steroid inhibited the release of these metabolites stimulated by both FMLP and PAF. The steroid inhibited iLTC4 release induced by the highest concentration of PAF (10(-6)M) but did not inhibit iLTC4 release stimulated by either 10(-7) M PAF, FMLP, or anti-IgE. Because neither FMLP nor PAF caused the release of PGD2 or TXB2 from purified human lung mast cells, and because they also failed to induce histamine release from lung fragments, it is suggested that these stimuli produce PGD2 and TXB2 release in lung fragments through an action on a cell distinct from the mast cell. This suggestion is supported by the selective inhibition of the release of these arachidonic acid metabolites by dexamethasone. We suggest that the inhibitory action of steroids on arachidonic acid metabolite in human lung fragments contributes to their therapeutic efficacy in pulmonary diseases.
Schleimer
R P
RP
Davidson
D A
DA
Lichtenstein
L M
LM
Adkinson
N F
NF
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology; D006801:Humans; D007073:Immunoglobulin E / Q000502:physiology; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000502:physiology; D011448:Prostaglandin Antagonists / Q000494:pharmacology*; D015230:Prostaglandin D2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011457:Prostaglandins D / Q000378:metabolism; D011460:Prostaglandins F / Q000378:metabolism; D013189:SRS-A / Q000378:metabolism; D013929:Thromboxane B2 / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D001095:Arachidonic Acids; D010972:Platelet Activating Factor; D011448:Prostaglandin Antagonists; D011457:Prostaglandins D; D011460:Prostaglandins F; D013189:SRS-A; D016718:Arachidonic Acid; D007073:Immunoglobulin E; D013929:Thromboxane B2; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003907:Dexamethasone; D011451:Prostaglandin-Endoperoxide Synthases; D015230:Prostaglandin D2; C100006:prostaglandin F1